Skip Navigation

COVID-19 Update

Exploring New Treatments for Bladder Cancer

MVAC in Organ-Confined Bladder Cancer Based on p53 Status: “The p53 Trial”

The p53 tumor-suppressor gene is located on chromosome number 17. Figure 1. Each human cell contains 23 pairs of chromosomes that can be distinguished by size and by unique banding patterns. The p53 tumor-suppressor gene is located on chromosome number 17. (National Institutes of Health)

This is an important study designed to provide better understanding of bladder cancer and how to treat patients with this disease. This trial is funded by the National Cancer Institute and will enroll more than 500 patients in about three years from over 30 hospitals around the world.

Background information: Like all tumors, the development of bladder cancer occurs through various mechanisms, which usually involve a change in one of your genes. Genes are like blueprints for our bodies. They contain information that determines our appearance and many aspects of our health. Chromosomes are the packages of genes found in our cells. Like all cancers, bladder cancer develops when alterations of the genes accumulate over time. The most common gene alteration found in tumors occurs in a gene called p53. The p53 gene is located on chromosome number 17 (see Figure 1). The normal function of the p53 gene is to prevent the development of tumor growth, which is why the chance of developing a tumor increases when the p53 gene is altered.

An abnormality of the p53 gene occurs in about 40 percent of patients with bladder cancer that has invaded into the bladder wall. Some studies suggest that those bladder tumors with an abnormal p53 gene (also called p53 altered or p53+ gene) may be slightly more aggressive and therefore pose a greater risk for tumor recurrence after removal of the bladder.

Cross section of the bladder wall Figure 2. Cross section of the bladder wall. The stages of tumors that will be evaluated in this study are the P1, P2a and P2b tumors. (Can Res 1977:37:2838-2842.

Purpose of the p53 trial: This study aims to determine whether patients with tumors containing a normal p53 gene live longer than patients with tumors containing an abnormal p53 gene. It will also demonstrate whether chemotherapy can improve the survival of patients with tumors containing an abnormal p53 gene.

To get involved in the study: Individuals who meet certain requirements will be invited to participate in this study. Once you have completed surgery with the total removal of your bladder and tumor (cystectomy), your physician will determine if your bladder tumor is limited within the wall of the bladder (organ confined) and has not spread through the wall or to any other part of your body (see Figure 2). Once it is determined that you are eligible for the trial, you may sign up for the trial. This will occur within nine weeks following your surgery.

Once you have signed up (registered) for the p53 trial (see Figure 3): Upon registration, your bladder tumor will be studied to determine if there is an alteration in the p53 gene. To do this, a sample of your tumor (removed at cystectomy) will be sent to a laboratory at the University of Southern California (USC) for special genetic analysis. This information will be kept confidential by the investigators and the research committee. Specific study-related information will be made available to the National Cancer Institute, the U.S. Food and Drug Administration, USC and the hospital where you are treated. If the results of this study are published in medical literature, you will be identified by name.

If your bladder tumor contains a normal p53 gene, you will not receive any additional therapy and you will be observed with a standard follow-up schedule. Currently, close follow-up after surgery is the standard of care for individuals with organ-confined bladder cancer.

If your bladder tumor has an abnormal p53 gene, you will then be selected to receive either additional therapy (chemotherapy) or monitored with standard follow-up care. We will use a computer program to determine whether you will be selected for standard follow-up care or chemotherapy. This process is called randomization.

The randomization process: If your bladder tumor is found to have an abnormal p53 gene, and you have decided to become involved in the study, you will then be randomized. This will occur within 10 weeks following your surgery.

Randomization is a procedure similar to flipping a coin. You will be selected for one of two options. This selection is not determined by your physician — it is made by a computer. The options will be either standard follow-up care or additional treatment with chemotherapy. Your chances of being selected for either of the two treatment options are equal.

The timing and dosage of chemotherapy: If you are randomized to receive chemotherapy, this will begin within 12 weeks following your surgery. This will allow ample time to heal from your operation prior to beginning the chemotherapy.

You will receive a total of three cycles of chemotherapy. This will include about 12 days of chemotherapy over the course of three months. The chemotherapy will be administered though a vein by your medical oncologist, either as an outpatient or an inpatient. You will be monitored and followed closely during and after your treatment.

Standard follow-up care: If you are selected for standard follow-up care, you will be monitored carefully. Currently, observation (no additional treatment) is the accepted standard of care for patients with this type of bladder cancer following surgery.

However, if your tumor returns (recurs), you will be provided with the best available treatment at that time.

The results of this trial will be important in the future treatment of patients and the better understanding of bladder cancer. Furthermore, we would like to express that both chemotherapy and standard follow-up are very acceptable forms of therapy.

back to top button